Literature DB >> 2382246

Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens.

D R Baldwin1, J M Andrews, J P Ashby, R Wise, D Honeybourne.   

Abstract

In a study of 58 patients the concentrations of cefixime, a new oral cephem antibiotic, in bronchial mucosa were 35-40% of the concentrations found in simultaneously collected serum samples. The antibiotic was often undetectable in sputum despite a highly sensitive assay.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2382246      PMCID： PMC462490          DOI： 10.1136/thx.45.5.401

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  7 in total

Review 1.  Bacterial colonization: pathogenesis and clinical significance.

Authors:  L B Palmer
Journal:  Clin Chest Med       Date:  1987-09       Impact factor: 2.878

2.  Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa.

Authors:  D Honeybourne; J M Andrews; J P Ashby; R Lodwick; R Wise
Journal:  Thorax       Date:  1988-09       Impact factor: 9.139

3.  Penetration of cefaclor into bronchial mucosa.

Authors:  G E Marlin; A J Nicholls; G R Funnell; R Bradbury
Journal:  Thorax       Date:  1984-11       Impact factor: 9.139

Review 4.  Penetration of antibiotics into respiratory secretions.

Authors:  J E Pennington
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

5.  Penetration of antibiotics into the respiratory tree.

Authors:  E Bergogne-Berezin
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

6.  Penetration of piperacillin into bronchial mucosa and sputum.

Authors:  G E Marlin; K R Burgess; J Burgoyne; G R Funnell; M D Guinness
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

7.  The fimbrial and non-fimbrial haemagglutinins of Escherichia coli.

Authors:  J P Duguid; S Clegg; M I Wilson
Journal:  J Med Microbiol       Date:  1979-05       Impact factor: 2.472
  7 in total
  7 in total

Review 1.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Cost-effectiveness and value of an IV switch.

Authors:  P Jewesson
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 3.  Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

Authors:  A Markham; R N Brogden
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

5.  Penetration of amoxycillin/clavulanic acid into bronchial mucosa with different dosing regimens.

Authors:  I M Gould; G Harvey; D Golder; T M Reid; S J Watt; J A Friend; J S Legge; J G Douglas
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

6.  Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection.

Authors:  P J Cook; J M Andrews; J Woodcock; R Wise; D Honeybourne
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

7.  Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections.

Authors:  M Cazzola; M G Matera; C F Donner
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.